LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

QuidelOrtho Formed by Combining Quidel and Ortho

By LabMedica International staff writers
Posted on 31 May 2022
Image: QuidelOrtho formed by the completion of transaction combining Quidel and Ortho Clinical Diagnostics (Photo courtesy of QuidelOrtho)
Image: QuidelOrtho formed by the completion of transaction combining Quidel and Ortho Clinical Diagnostics (Photo courtesy of QuidelOrtho)

QuidelOrtho Corporation (San Diego, CA, USA) has announced the completion of the transaction combining Quidel Corporation (San Diego, CA, USA) and Ortho Clinical Diagnostics (Raritan, NJ, USA), creating QuidelOrtho, a leading in vitro diagnostics company. In December 2021, Quidel acquired Ortho in a USD 6 billion transaction that aims to unite technologies and platforms to offer expanded access to clinical chemistry, immunoassay, molecular diagnostics, immunohematology, donor screening and point-of-care diagnostic offerings. 

QuidelOrtho’s comprehensive product portfolio covers a wide range of point-of-care tests for infectious diseases, critical cardiac health and autoimmune biomarkers, and a host of clinical and at-home products to detect COVID-19. QuidelOrtho’s core competencies and capabilities include immunoassay development, automated manufacturing, monoclonal antibody characterization and development, molecular assay development, lab-based in vitro diagnostics, blood bank solutions and transfusion pre-screening.

QuidelOrtho’s current products fall generally into these categories: (1) visually-read lateral flow, with expertise in infectious disease and reproductive health; (2) direct fluorescent antibodies (DFA), with expertise in infectious disease and virology; (3) micro-titer production, with a focus on bone and complement pathway markets; (4) fluorescent immunoassay products (Sofia); (5) molecular diagnostic products including the flagship Savanna, an integrated molecular diagnostic system; (6) immunodiagnostics, clinical chemistry and integrated testing systems to serve diagnostic labs of all sizes (VITROS Systems); (7) immunodiagnostic donor screening systems and services that drive blood safety (Ortho Summit/VERSEIA/VITROS Systems); (8) pre-transfusion testing that automates blood bank workload (VITROS 3600) with software to standardize operations, simplify tasks, and improve productivity (ORTHO CONNECT); and (9) a combination of service, expertise, technology and data-driven solutions to drive effective, efficient labs (Ortho Care Services & Informatics).

“We are very excited to bring together the talented and experienced teams of both Quidel and Ortho who share a commitment to the employees, customers, patients, and the communities we serve,” said Douglas Bryant, Chairman and Chief Executive Officer of QuidelOrtho. “There is a lot of important work ahead of us to deliver on our targeted synergies and new product introductions and we are energized and poised to excel in our combined mission to deliver advanced diagnostics to improve human health.”

Related Links:
QuidelOrtho Corporation 
Quidel Corporation 
Ortho Clinical Diagnostics 

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more